PracticeVideosBlogFlashcardsEspañol
All Practice Exams

Free Practice Questions for CMN Neurología

Exam-style questions and explanations by OpenExamPrep.

✓ No registration✓ No credit card
100+ Questions
100% Free

Loading practice questions...

Same family resources

Explore More CONACEM Medical Specialty Board Certification Examinations (Mexico)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Consejo Mexicano de Certificación en Pediatría — Certificación en Pediatría (Mexico)

Practice Questions

Consejo Mexicano de Medicina de Urgencias — Certificación en Medicina de Urgencias (Mexico)

Practice Questions

Consejo Mexicano de Psiquiatría — Certificación en Psiquiatría (Mexico)

Practice Questions

Consejo Mexicano de Radiología e Imagen — Certificación en Radiología e Imagen (Mexico)

Practice Questions

Consejo Mexicano de Cirugía General — Certificación en Cirugía General (Mexico)

Practice Questions

Consejo Mexicano de Dermatología — Certificación en Dermatología (Mexico)

Practice Questions
Exam Review

Key Facts: CMN Neurología Exam

2027

Next first-time certification convocatoria (pending when checked)

CMN Primera certificación

5 years

Recertification cycle

CMN Recertificación

250 points

Minimum for recertification by points

CMN Recertificación

MXN 12,000

Recertification by exam fee (from 15 May 2026)

CMN Recertificación

MXN 9,000

Recertification by points fee (from 15 May 2026)

CMN Recertificación

The CMN certification is the CONACEM-recognized board process for neurology in Mexico. The 2027 first-time certification convocatoria had not been published when checked on 29 September 2026; recertification is required every 5 years by points (MXN 9,000) or by exam (MXN 12,000).

Sample CMN Neurología Practice Questions

Try these sample questions to review concepts for the CMN Neurología exam. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A 64-year-old man presents with sudden-onset right hemiparesis and expressive aphasia that started 90 minutes ago. Non-contrast head CT demonstrates an early ischemic change in the left insular ribbon and lentiform nucleus with an ASPECTS score of 8, and no hemorrhage. His blood pressure is 165/95 mmHg, and point-of-care blood glucose is 128 mg/dL. He has no prior history of stroke, surgery, or coagulopathy. What is the most appropriate immediate reperfusion therapy?
A.Intravenous recombinant tissue plasminogen activator (alteplase 0.9 mg/kg)
B.Endovascular thrombectomy alone without prior intravenous thrombolysis
C.Oral aspirin 325 mg and clopidogrel 300 mg loading dose immediately
D.Intravenous unfractionated heparin bolus followed by continuous infusion
Explanation: Intravenous alteplase (0.9 mg/kg, maximum 90 mg; 10% bolus over 1 minute and 90% over 60 minutes) or tenecteplase is the standard-of-care first-line reperfusion therapy for eligible patients presenting within 4.5 hours of ischemic stroke symptom onset. An ASPECTS score of 8 indicates limited early ischemic change (≥6 is favorable), BP is below 185/110 mmHg, and there are no contraindications. Vascular imaging should proceed promptly to assess for large vessel occlusion (LVO) for possible mechanical thrombectomy, but IV thrombolysis must not be delayed.
2A 71-year-old woman was last known well at 22:00 when she went to sleep. Upon waking at 06:00, her family noticed dense left hemiplegia and neglect (NIHSS score 16). Non-contrast CT at 07:00 shows no hemorrhage with an ASPECTS of 9. CT perfusion demonstrates an ischemic core of 15 mL (CBF <30%) and a hypoperfused penumbra of 85 mL (Tmax >6 seconds). CTA confirms an occlusion of the right M1 middle cerebral artery. Based on the DAWN and DEFUSE-3 trials, which treatment is indicated?
A.Supportive care in the neurological ICU with permissive hypertension only
B.Mechanical thrombectomy with a stent retriever and/or aspiration catheter
C.Intravenous alteplase administered off-label due to the penumbral mismatch
D.Emergency decompressive hemicraniectomy prior to vessel recanalization
Explanation: The DAWN (up to 24 hours) and DEFUSE-3 (up to 16 hours) trials established the efficacy of mechanical thrombectomy in wake-up or late-presenting strokes with large vessel anterior circulation occlusions when advanced imaging (CTP or MRI DWI-PWI) demonstrates a small ischemic core (<70 mL) and a substantial perfusion-core mismatch ratio (≥1.8 in DEFUSE-3, or clinical-core mismatch in DAWN). This patient has a 15 mL core and 70 mL salvageable penumbra, making her an ideal candidate for mechanical thrombectomy.
3A 59-year-old man presents with acute left hemiparesis. Non-contrast CT reveals a spontaneous 28 mL hematoma in the right putamen with 2 mm of midline shift and no intraventricular extension. His initial Glasgow Coma Scale (GCS) score is 11. What is his 30-day mortality risk stratification according to the Hemphill Intracerebral Hemorrhage (ICH) Score?
A.ICH Score 0 (0% 30-day mortality)
B.ICH Score 3 (72% 30-day mortality)
C.ICH Score 1 (13% 30-day mortality)
D.ICH Score 2 (26% 30-day mortality)
Explanation: The Hemphill Intracerebral Hemorrhage (ICH) Score stratifies 30-day mortality based on five clinical and radiological components: Glasgow Coma Scale score (GCS 3–4 = 2 points, 5–12 = 1 point, 13–15 = 0 points), ICH volume (≥30 mL = 1 point, <30 mL = 0 points), intraventricular hemorrhage (present = 1 point, absent = 0 points), infratentorial origin (yes = 1 point, supratentorial = 0 points), and age (≥80 years = 1 point, <80 years = 0 points). This patient scores 1 point for GCS 11 (bracket 5–12), 0 points for volume 28 mL (<30 mL), 0 points for absent IVH, 0 points for supratentorial putaminal location, and 0 points for age 59 (<80 years), yielding a total ICH score of 1 point. This corresponds to an estimated 30-day mortality of approximately 13%.
4A 68-year-old woman with non-valvular atrial fibrillation taking dabigatran 150 mg twice daily presents 2 hours after acute onset of right hemiplegia and stupor. Non-contrast head CT reveals a 45 mL left lobar intracerebral hemorrhage. Her activated partial thromboplastin time (aPTT) and thrombin time are markedly prolonged. What is the specific reversal agent of choice?
A.Andexanet alfa
B.Four-factor prothrombin complex concentrate (4F-PCC)
C.Intravenous protamine sulfate
D.Idarucizumab
Explanation: Idarucizumab is a humanized monoclonal antibody fragment (Fab) that specifically binds dabigatran and its metabolites with an affinity ~350 times higher than that of thrombin. It is administered as two consecutive 2.5 g intravenous doses (total 5 g) and reverses dabigatran's anticoagulant effect within minutes. Andexanet alfa was developed to reverse factor Xa inhibitors (apixaban, rivaroxaban) and was withdrawn from the US market in December 2025,4F-PCC is second-line for dabigatran when idarucizumab is unavailable, and protamine reverses heparin.
5A 48-year-old man presents with the sudden onset of the 'worst headache of his life' accompanied by neck stiffness and vomiting. A non-contrast head CT performed 10 hours after onset is completely normal. What is the most appropriate next diagnostic step?
A.Discharge with oral sumatriptan and a diagnosis of acute migraine
B.Lumbar puncture to examine cerebrospinal fluid opening pressure, red blood cells, and xanthochromia
C.Repeat non-contrast head CT scan in 24 hours
D.Empiric intravenous broad-spectrum antibiotics and dexamethasone
Explanation: In a patient with thunderclap headache suspicious for subarachnoid hemorrhage (SAH) and a negative non-contrast head CT, the next step depends on timing. A normal modern CT performed within 6 hours of onset and read by an experienced radiologist is nearly 100% sensitive and effectively excludes SAH (AHA/ASA 2023). Beyond 6 hours, as here, sensitivity falls, so lumbar puncture is indicated to look for elevated RBC counts that do not clear across serial tubes and for xanthochromia (bilirubin from metabolized hemoglobin, detectable from about 6-12 hours after the bleed); CT angiography is an accepted alternative in many centers.
6A 52-year-old woman undergoes successful endovascular coiling of a ruptured anterior communicating artery aneurysm. On post-bleed day 6, she develops subtle confusion, pronator drift of the right arm, and expressive hesitations. Transcranial Doppler shows mean flow velocity in the left MCA of 210 cm/s with a Lindegaard ratio of 4.5. Which medication has proven Level 1A evidence for improving neurological outcomes and reducing delayed cerebral ischemia (DCI)?
A.Intravenous magnesium sulfate infusion titrated to 2.5 mmol/L
B.Hypervolemic hyperdynamic hemodilution ('triple-H' therapy)
C.Oral nimodipine 60 mg every 4 hours for 21 days
D.Intravenous methylprednisolone 1 g daily for 5 days
Explanation: Oral nimodipine (60 mg every 4 hours for 21 days) is the only pharmacological agent conclusively proven in randomized controlled trials to reduce the risk of secondary cerebral ischemia and improve functional outcomes following aneurysmal subarachnoid hemorrhage (Level 1A recommendation). Its benefit is mediated primarily through neuroprotection and microvascular tone rather than prevention of large-vessel vasospasm.
7A 26-year-old woman taking combined oral contraceptives presents with a 4-day history of progressively worsening holocranial headache, visual obscurations, and a new generalized tonic-clonic seizure. Bilateral funduscopic examination reveals severe papilledema. MRI venography demonstrates lack of flow void and filling defects within the superior sagittal sinus and right transverse sinus, with bilateral parasagittal frontal venous hemorrhagic infarctions. What is the primary initial medical treatment?
A.Emergency decompressive craniectomy prior to any medical therapy
B.Intravenous high-dose dexamethasone to reduce vasogenic edema
C.Immediate placement of a permanent ventriculoperitoneal shunt
D.Therapeutic anticoagulation with adjusted-dose unfractionated heparin or low-molecular-weight heparin
Explanation: The cornerstone of treatment for cerebral venous thrombosis (CVT)—even in the presence of venous hemorrhagic infarction—is therapeutic anticoagulation with weight-adjusted low-molecular-weight heparin (LMWH) or IV unfractionated heparin. Multiple randomized trials and clinical practice guidelines confirm that anticoagulation prevents thrombus propagation, facilitates recanalization, and does not increase hematoma expansion, leading to better functional outcomes.
8Which of the following baseline neuroimaging findings corresponds to the loss of 1 point in the 10-point Alberta Stroke Program Early CT Score (ASPECTS) system?
A.Early hypoattenuation or sulcal effacement involving the insular cortex (insular ribbon sign)
B.Hypoattenuation isolated strictly to the anterior cerebral artery territory
C.Hyperattenuation within the lumen of the basilar artery
D.Effacement of the contralateral cerebellar hemisphere
Explanation: The ASPECTS score divides the middle cerebral artery (MCA) territory into 10 regions on non-contrast CT across two standardized axial slices (ganglionic and supraganglionic): Caudate (C), Lentiform (L), Internal capsule (IC), Insular ribbon (I), and MCA cortex M1, M2, M3 (at ganglionic level), and M4, M5, M6 (at supraganglionic level). Each region showing parenchymal hypoattenuation or focal sulcal effacement subtracts 1 point from 10. The insular cortex is region 'I'.
9A 74-year-old man presents with acute left-sided weakness. Blood pressure is 215/120 mmHg. He is within 2 hours of symptom onset and has no other contraindications to intravenous thrombolysis. What is the recommended target blood pressure threshold that must be safely attained before administering IV alteplase?
A.Systolic <160 mmHg and diastolic <90 mmHg
B.Systolic <200 mmHg and diastolic <110 mmHg
C.Systolic <185 mmHg and diastolic <110 mmHg
D.Systolic <140 mmHg and diastolic <80 mmHg
Explanation: According to AHA/ASA acute ischemic stroke guidelines, blood pressure must be reduced to systolic <185 mmHg and diastolic <110 mmHg prior to initiating intravenous thrombolytic therapy. Once thrombolysis is initiated, blood pressure must be maintained below 180/105 mmHg for at least the next 24 hours to prevent symptomatic hemorrhagic transformation.
10A 62-year-old diabetic woman presents with sudden onset of right facial numbness, dysphagia, hoarseness, right-sided Horner syndrome, right cerebellar ataxia, and loss of pain and temperature sensation on the left side of her body. Where is the primary vascular lesion located?
A.Paramedian branch of the basilar artery (Millard-Gubler syndrome)
B.Penetrating lenticulostriate branch of the left MCA (pure motor stroke)
C.Anterior spinal artery territory in the ventral medulla (Dejerine syndrome)
D.Posterior inferior cerebellar artery (PICA) or vertebral artery (Wallenberg syndrome)
Explanation: This patient exhibits the classic clinical tetrad of lateral medullary syndrome (Wallenberg syndrome): ipsilateral Horner syndrome (sympathetic tract), ipsilateral facial sensory loss (spinal trigeminal nucleus), contralateral body hemi-hypalgesia (spinothalamic tract), ipsilateral ataxia (inferior cerebellar peduncle), and bulbar palsy with dysphagia/hoarseness (nucleus ambiguus). This syndrome is caused by occlusion of the vertebral artery (most common, ~70%) or the posterior inferior cerebellar artery (PICA).

About the CMN Neurología Exam

Independent study practice by OpenExamPrep for the certification exam of the Consejo Mexicano de Neurología, A.C. (CMN), a CONACEM-recognized specialty council. This bank is an independent English-language MCQ study adaptation built on clinical scenarios, anatomical localization, neuroimaging, neuropharmacology and current international guidelines; it is not an official translation or simulation of the Spanish-language CMN exam, whose 2027 format has not yet been published.

Exam sponsor: Consejo Mexicano de Neurología, A.C. (CMN). The requirements and fees below concern the certification or admission exam, separate from our free practice resources.

Assessment

The CMN grants first-time certification by examination. As of 29 September 2026 its certification page only announces that the 2027 convocatoria is pending, so the exam format, item count, time limit, venue, fee and pass mark have not been published. Recertification every 5 years is by points or by exam.

Time Limit

Not published

Passing Score

not-published

Exam / Certification Fees

Not published for first-time certification (recertification by exam MXN 12,000; by points MXN 9,000)

Exam sponsor website

Fees, eligibility, and exam policies can change. Confirm them with the exam sponsor before applying or paying.

Official sources

Our practice resources: topics covered

We aim to reflect publicly available exam outlines and topic information in our study resources. Coverage, format, and difficulty may differ from the actual exam, and we cannot guarantee that every detail is accurate or current. Confirm exam requirements, fees, and policies with the official exam sponsor.

Core domain (weight not published)

Enfermedad Vascular Cerebral

Acute ischemic stroke diagnostic evaluation, ASPECTS scoring, intravenous thrombolysis inclusion and exclusion criteria, endovascular thrombectomy (DAWN and DEFUSE-3 trial parameters), secondary stroke prevention, spontaneous intracerebral hemorrhage, ICH score calculation, acute blood pressure control, hematoma expansion risk, anticoagulant reversal agents, aneurysmal subarachnoid hemorrhage diagnosis and complications, nimodipine vasospasm prophylaxis, and cerebral venous sinus thrombosis diagnostic and anticoagulant therapy

Core domain (weight not published)

Epilepsia y Trastornos Paroxísticos

ILAE classification of seizures and epilepsy syndromes, electroencephalographic correlates, selection of anti-seizure medications across focal, generalized, and myoclonic epilepsies, teratogenic risks of valproate and antiepileptic safety during pregnancy, step-wise management of convulsive and non-convulsive status epilepticus (first-line IV benzodiazepines, second-line IV anti-seizure medications, third-line continuous anesthetics), and clinical differentiation of psychogenic non-epileptic seizures

Core domain (weight not published)

Enfermedades Desmielinizantes e Infecciosas del SNC

Multiple sclerosis diagnosis applying the 2017 McDonald criteria, dissemination in time and space, cerebrospinal fluid analysis and oligoclonal bands, acute relapse management, disease-modifying therapies, neuromyelitis optica spectrum disorder (anti-aquaporin-4 vs anti-MOG antibody distinction, rituximab, eculizumab), neurocysticercosis epidemiology and staging (Del Brutto diagnostic criteria, vesicular, colloidal, and calcified forms, anthelmintic therapy with albendazole or praziquantel paired with corticosteroid coverage), acute community-acquired bacterial meningitis, and herpes simplex virus encephalitis

Core domain (weight not published)

Trastornos del Movimiento y Demencias

Parkinson disease clinical diagnosis (bradykinesia, rigidity, resting tremor, postural instability), levodopa pharmacodynamics, motor fluctuations and dyskinesias, dopamine agonists and impulse control disorders, deep brain stimulation patient selection, atypical parkinsonian syndromes (progressive supranuclear palsy, multiple system atrophy, corticobasal syndrome), Huntington disease genetics and chorea management, tremor syndromes, Alzheimer disease biomarker profiles (amyloid-beta 42/40 ratio, p-tau, t-tau), cholinesterase inhibitors, memantine, amyloid-targeting monoclonal antibodies, frontotemporal lobar degeneration behavioral and language variants, dementia with Lewy bodies, and rapid cognitive decline in Creutzfeldt-Jakob disease (14-3-3 protein, RT-QuIC)

Core domain (weight not published)

Enfermedades Neuromusculares, Cefaleas y Neurooncología

Myasthenia gravis serological subtypes (anti-acetylcholine receptor, anti-MuSK), tensilon/edrophonium test historical context, myasthenic crisis vs cholinergic crisis, indications for thymectomy, Guillain-Barré syndrome variants, Brighton criteria, albuminocytological dissociation, IVIG vs plasma exchange indications, primary headache disorders (migraine diagnostic criteria, acute and preventive therapies including CGRP receptor antagonists and monoclonal antibodies, cluster headache high-flow oxygen and subcutaneous sumatriptan), trigeminal neuralgia pharmacotherapy, glioblastoma multiforme molecular markers (IDH mutation, MGMT promoter methylation), and brain metastasis management

Preparing for the CMN Neurología Exam

What You Need to Know

  • Passing score: not-published
  • Assessment: The CMN grants first-time certification by examination. As of 29 September 2026 its certification page only announces that the 2027 convocatoria is pending, so the exam format, item count, time limit, venue, fee and pass mark have not been published. Recertification every 5 years is by points or by exam.
  • Time limit: Not published
  • Exam / certification fees: Not published for first-time certification (recertification by exam MXN 12,000; by points MXN 9,000) Official sources

Using Our Practice Resources

  • Work through all 100 available questions
  • Review every answer and explanation
  • Track weak areas and revisit them
  • Use our AI tutor for tough concepts

CMN Neurología: Suggested Study Strategy

1Master the acute ischemic stroke reperfusion timeline: IV thrombolysis within 4.5 hours of last known well (with imaging-selected extended windows), ASPECTS scoring, thrombectomy up to 24 hours under DAWN/DEFUSE-3 criteria (and for basilar occlusion per ATTENTION/BAOCHE), and early DOAC timing after AF-related stroke (ELAN, OPTIMAS).
2Review the step-wise management of convulsive status epilepticus: IV lorazepam or diazepam as first-line (0-5 min), followed by full weight-based IV levetiracetam, fosphenytoin, or sodium valproate (5-20 min), and continuous anesthetic infusions (propofol, midazolam) with EEG monitoring if refractory.
3Know the McDonald criteria for multiple sclerosis (2017, updated 2024), including dissemination in space and time and the role of CSF oligoclonal bands, and the distinctions from NMOSD (anti-AQP4) and MOGAD (anti-MOG).
4Understand the clinical and neuroimaging staging of neurocysticercosis common in Mexican clinical practice (vesicular, colloidal vesicular, granular nodular, calcified), applying Del Brutto diagnostic criteria and knowing when anthelmintic therapy with albendazole or praziquantel requires upfront corticosteroid coverage to prevent cerebral edema.
5Know the diagnostic criteria and red flags for atypical parkinsonian syndromes: vertical supranuclear gaze palsy and early falls in PSP, prominent autonomic dysfunction and cerebellar signs with 'hot cross bun' sign in MSA, and asymmetric alien limb phenomenon with cortical sensory loss in CBD.

Frequently Asked Questions

What is the Consejo Mexicano de Neurología certification exam?

It is the board certification process of the Consejo Mexicano de Neurología, A.C. (CMN), one of the specialty councils recognized by CONACEM. First-time certification is by examination, and certified neurologists renew every 5 years.

When is the next first-time certification exam?

As of 29 September 2026, the CMN first-certification page asks candidates to wait for the 2027 certification exam convocatoria. The date, venue, fee, format and requirements will be announced there.

How does recertification work?

The CMN offers recertification by points or by exam. By points requires at least 250 points from the last 5 years across clinical, academic, continuing education, teaching and research activities, with a fee of MXN 9,000 from 15 May 2026, and must be completed within 6 months of the certificate expiring. After that, or without enough points, recertification is by exam, with a fee of MXN 12,000.

What is the question count, duration and pass mark?

The CMN has not published an item count, duration or pass mark for the first-time certification exam.

Why is this practice bank in English?

The CMN exam is conducted in Spanish. This OpenExamPrep bank is an independent English-language MCQ study adaptation for reviewing the clinical content; it is not an official translation or simulation of the CMN exam.